Peritoneal carcinomatosis from colorectal cancer

Jayne, David; Fook, Stephanie; Loi, Carol; Seow‐Choen, Francis

doi:10.1046/j.1365-2168.2002.02274.x

Cited by 743 publications

(491 citation statements)

References 16 publications

Supporting

Mentioning

455

Contrasting

Unclassified

Order By: Relevance

“…Moreover, 25% of patients with recurrence have disease confined to the peritoneal cavity [47]. PC arising from CRC has long been considered as a generalized disease and has been treated with systemic chemotherapy.…”

Section: Mcamentioning

confidence: 99%

Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: A Review of Current Therapy

Winder

Lenz

2010

The Oncologist

View full text Add to dashboard Cite

Peritoneal carcinomatosis has been considered a terminal disease with a median survival time of 5.2-12.6 months. Systemic chemotherapy and cytoreductive surgery (CRS) have long been used to treat macroscopic disease, with limited success. However, a comprehensive treatment approach involving cytroreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) has evolved into a novel approach for peritoneal carcinomatosis. Surgery removes the primary cancer and any dissemination within the peritoneal cavity and adjuvant HIPEC eradicates macroscopic or microscopic tumor residue, thus reducing the risk for recurrence. This approach offers a new potential treatment option for patients with metastatic disease confined to the peritoneum. The present review provides an update of the most recent data on the current therapy for pseudomyxoma peritonei (PMP) and mucinous colorectal adenocarcinoma (MCA) with metastatic disease confined to the peritoneum. The Oncologist 2010;15:836 -844

show abstract

Section: Mcamentioning

confidence: 99%

Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: A Review of Current Therapy

Winder

Lenz

2010

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Among the first to suggest using preventive perioperative intraperitoneal chemotherapy in colorectal cancer were Jayne et al several years ago [74]. Various investigators have reproposed this strategy particularly in patients with free endoperitoneal cancer cells [75,76].…”

Section: Proactive Management Of Peritoneal Metastases From Colorectamentioning

confidence: 99%

“…In the PROMENADE trial we include patients with pT3 tumors and have several reasons for doing so. First consensus experience from surgeons treating peritoneal metastases from colorectal cancer suggests that peritoneal spread correlates with the same rate in pT3 and in pT4 tumors [65,74,94]. Second, correctly assessing serosal invasion in colorectal cancer is difficult and can require extensive tissue sampling.…”

Section: Proactive Management Of Peritoneal Metastases From Colorectamentioning

confidence: 99%

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Sammartino

Biacchi

Cornali

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

An integrated treatment strategy using peritonectomy procedures plus hyperthermic intraperitoneal chemotherapy (HIPEC) is now a clinical standard of care in selected patients with peritoneal metastases and primary peritoneal tumors. This comprehensive approach can offer many patients, who hitherto had no hope of cure, a good quality of life and survival despite limited morbidity. The increasingly successful results and chance of interfering in the natural history of disease has prompted research to develop for some clinical conditions a therapeutic strategy designed to prevent malignant peritoneal dissemination before it becomes clinically evident and treat it microscopically (tertiary prevention). The main factor governing successful cytoreductive surgery and predicting outcome is the extent of peritoneal spread assessed with the peritoneal cancer index (PCI). In peritoneal metastases from colorectal and gastric cancer the PCI score acquires a specific role acting as the cut-off between patients who can undergo curative surgery or palliation. Long-term results show that the only group enjoying favorable results are patients with limited disease (a statistical minority). By applying to appropriately selected patients with primary malignancies a proactive management strategy including HIPEC we can treat patients with microscopic peritoneal dissemination and therefore at PCI 0. Among treated conditions pseudomyxoma peritonei enjoys the best results. But a major future advance comes from identifying among lesions at major risk of pseudomyxoma.

show abstract

“…The liver and the peritoneal surfaces are the most frequent sites of metastatic disease of colorectal cancer in order of sequence [1]. Peritoneal carcinomatosis is not considered a real metastatic disease but only a dissemination of cancer [2,3].…”

Section: Introductionmentioning

confidence: 99%

Peritoneal Colorectal Carcinomatosis Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Tentes¹,

Korakianitis²,

Pallas³

et al. 2012

View full text Add to dashboard Cite

Background-Aims: Peritoneal colorectal carcinomatosis is a potentially curative disease. The purpose of the study is the retrospective analysis of survival of the patients with peritoneal colorectal carcinomatosis that underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy and the identification of prognostic variables of the disease. Patients-Methods: Patients with primary or recurrent colorectal cancer and peritoneal carcinomatosis were included in the study. Clinical variables were correlated to survival, recurrence, hospital mortality, and morbidity. Results: From 2000-2010, 28 patients underwent 33 cytoreductive operations. The hospital mortality and morbidity rate was 9.1% and 45.5% respectively. The overall 5-year and median survival time was 29.2% and 19 months respectively. The extent of peritoneal carcinomatosis (p = 0.0003) and the completeness of cytoreduction (p = 0.0002) were related to survival. The completeness of cytoreduction (p = 0.003) was the single prognostic variable of survival. The recurrence rate was 42.4% and the use of systemic chemotherapy was identified as the single prognostic variable of recurrence (p = 0.047). Conclusions:Patients with limited extent of peritoneal colorectal carcinomatosis who undergo complete cytoreduction may be offered long-term survival.

show abstract

Peritoneal carcinomatosis from colorectal cancer

Abstract: Peritoneal carcinomatosis is a common mode of disease progression in patients with colorectal cancer. For the majority of patients the prognosis is poor, but a small number with localized disease may be suitable for further aggressive therapy.

Cited by 743 publications

References 16 publications

Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: A Review of Current Therapy

Mucinous Adenocarcinomas with Intra-Abdominal Dissemination: A Review of Current Therapy

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Peritoneal Colorectal Carcinomatosis Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Contact Info

Product

Resources

About